BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19863693)

  • 21. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
    Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
    Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells.
    Nishimura K; Matsumiya K; Miura H; Tsujimura A; Nonomura N; Matsumoto K; Nakamura T; Okuyama A
    Int J Androl; 2003 Jun; 26(3):175-9. PubMed ID: 12755996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression.
    Khan KM; Falcone DJ
    J Biol Chem; 1997 Mar; 272(13):8270-5. PubMed ID: 9079647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.
    Jeffers M; Rong S; Vande Woude GF
    Mol Cell Biol; 1996 Mar; 16(3):1115-25. PubMed ID: 8622656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autocrine and paracrine regulation of tissue inhibitor of metalloproteinases, transin, and urokinase gene expression in metastatic and nonmetastatic mammary carcinoma cells.
    Korczak B; Kerbel RS; Dennis JW
    Cell Growth Differ; 1991 Jul; 2(7):335-41. PubMed ID: 1782152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
    Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
    Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
    Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
    Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR; Beaulieu LM; Carter JC; Church FC
    Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
    Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
    Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Actinobacillus actinomycetemcomitans lipopolysaccharide regulates matrix metalloproteinase, tissue inhibitors of matrix metalloproteinase, and plasminogen activator production by human gingival fibroblasts: a potential role in connective tissue destruction.
    Bodet C; Andrian E; Tanabe S; Grenier D
    J Cell Physiol; 2007 Jul; 212(1):189-94. PubMed ID: 17299802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
    Testa JE
    Cancer Res; 1992 Oct; 52(20):5597-603. PubMed ID: 1327511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice.
    Seubert B; Grünwald B; Kobuch J; Cui H; Schelter F; Schaten S; Siveke JT; Lim NH; Nagase H; Simonavicius N; Heikenwalder M; Reinheckel T; Sleeman JP; Janssen KP; Knolle PA; Krüger A
    Hepatology; 2015 Jan; 61(1):238-48. PubMed ID: 25131778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-1β-stimulated urokinase plasminogen activator expression through NF-κB in gastric cancer after HGF treatment.
    Lee KH; Choi EY; Koh SA; Kim MK; Jang BI; Kim SW; Kim JR
    Oncol Rep; 2014 May; 31(5):2123-30. PubMed ID: 24626561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
    Lee KH; Hyun MS; Kim JR
    Clin Exp Metastasis; 2003; 20(6):499-505. PubMed ID: 14598883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
    Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
    Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
    Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.
    Wei L; Lun Y; Zhou X; He S; Gao L; Liu Y; He Z; Li B; Wang C
    Pharmacol Res; 2019 May; 143():73-85. PubMed ID: 30862605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
    Ried S; Jäger C; Jeffers M; Vande Woude GF; Graeff H; Schmitt M; Lengyel E
    J Biol Chem; 1999 Jun; 274(23):16377-86. PubMed ID: 10347197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.